Aerobic Interval vs Continuous Training on Heart Rate-Power Decoupling in Ischemic Heart Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorUniversidad Complutense de Madrid
About this trial
This study is a randomized, parallel-group clinical trial with assessor and statistical analyst blinding, conducted at a single center. Participants with stable ischemic heart disease enrolled in a cardiac rehabilitation program will be randomly allocated to one of two aerobic exercise interventions: long extensive continuous aerobic training (zone 2) or long extensive aerobic interval training (zone 3). Both groups will participate in supervised exercise sessions twice weekly for a period of 8 weeks, integrated into the standard cardiac rehabilitation program.
Assessments will be performed at baseline, immediately after the intervention period (8 weeks), and after a 4-week follow-up period without supervised training to evaluate potential detraining effects. The primary outcome is heart rate-power decoupling during a prolonged submaximal cycling exercise test, used as an indicator of cardiovascular efficiency. Secondary outcomes include heart rate response during submaximal exercise, exercise tolerance, heart rate recovery, blood pressure, functional capacity, quality of life, and adherence to the training program.
The objective of this study is to compare the effects of long extensive aerobic interval training versus long extensive continuous training on heart rate-power decoupling and related cardiovascular and functional outcomes in patients with ischemic heart disease undergoing cardiac rehabilitation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Confirmed diagnosis of cardiovascular disease requiring cardiac rehabilitation, with medical indication for a supervised exercise training program.
Killip class I or II (absence or mild heart failure)¹.
Absence of recent acute myocardial infarction (< 1 month) or presence of a stable previous infarction.
Stable and well-controlled cardiovascular symptoms.
Disqualifiers
Killip class > III (moderate to severe heart failure).
Recent acute myocardial infarction (< 1 month) with clinical instability.
Active anginal symptoms or decompensated heart failure.
Physical capacity < 5 METs on functional testing, indicating severely reduced exercise capacity.
Trial design
Design model
Parallel
Treatments tested in this trial
Intervention Group
Other interventionParticipants will undergo an 8-week aerobic interval training program on a cycle ergometer, consisting of two weekly supervised sessions of 90 minutes. Each session includes: Warm-up: 10-15 minutes of low-intensity continuous pedaling (≤60% max HR) and joint mobility exercises. Main aerobic interval training: 8 intervals of 3 minutes pedaling at 75-85% of maximum heart rate, each followed by 2 minutes of active recovery at 65-70% max HR. Total aerobic training duration approximately 40 minutes. Cool-down: 5-10 minutes of light pedaling and stretching. Heart rate, blood pressure, and oxygen saturation will be continuously monitored. Safety criteria for session interruption will be applied.
Control Group (A):
Other interventionParticipants will complete an 8-week continuous aerobic training program on a cycle ergometer, with two weekly supervised 90-minute sessions, including: Warm-up: 10-15 minutes of low-intensity continuous pedaling (≤60% max HR) and joint mobility exercises. Main aerobic continuous training: 40 minutes of continuous pedaling at 65-75% of maximum heart rate. Cool-down: 5-10 minutes of light pedaling and stretching. Monitoring and safety procedures as in the intervention group.
Treatment groups
48 Participants
are divided into 2 treatment groupsGroup A: Control Group: Extensive Continuous TrainingActive comparator 1 intervention
Group B: Long Extensive Interval TrainingExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in heart rate-power slope during a submaximal incremental cycling test
The heart rate-power slope will be assessed during a submaximal incremental cycling test performed on a cycle ergometer. The protocol will start at 20 W, with workload increases of 10 W every 2 minutes until submaximal termination criteria are reached. Heart rate will be continuously monitored using a validated chest strap device. The heart rate-power slope will be calculated as: (Heart rate\_initial - Heart rate\_final) / (Power\_initial - Power\_final) The result will be expressed in beats per minute per watt (bpm/W). Higher values indicate reduced cardiovascular efficiency.
Time frame
Baseline (Week 0), Post-intervention (Week 8), and Follow-up (Week 12)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: